Overview: Nicotinic acetylcholine receptors are members of the cys-loop superfamily of transmitter-gated ion channels that includes the GABA A , strychnine-sensitive glycine and 5-HT 3 receptors. All nicotinic receptors are formed as pentamers of subunits. Genes (Ensembl family ID ENSF00000000049) encoding a total of 17 subunits (a1-10, b1-4, d, e and g) have been identified. All subunits are of mammalian origin with the exception of a8 (avian). Each subunit possesses 4 TM domains. All a subunits possess two tandem cysteine residues near to the site involved in acetylcholine binding, and subunits not named a lack those tandem cysteines. The acetylcholine-binding site is formed by at least three peptide loops on the a subunit (principal component), and three on the adjacent subunit (complementary component). The determination of a high-resolution (2.7 Å ) crystal structure of the acetylcholine-binding protein from Lymnaea stagnalis, a structural homologue of the extracellular binding domain of a nicotinic receptor pentamer, has revealed the binding site in detail (reviewed by Karlin, 2002). Nicotinic receptors at the somatic neuromuscular junction of adult animals have the stoichiometry (a1) 2 b1ed, whereas an extrajunctional (a1) 2 b1gd receptor predominates in embryonic and denervated skeletal muscle. Other nicotinic receptors are assembled as combinations of a(2 -6) and b(2 -4) subunits. For a2, a3, a4 and b2 and b4 subunits, pairwise combinations of a and b (e.g. a3b4, a2b4) are sufficient to form a functional receptor in vitro, but more complex isoforms may exist in vivo. a5 and b3 subunits lack function when expressed pairwise, but participate in the formation of functional hetero-oligomeric receptors (e.g. a4a5ab2, a6b2b3) when co-expressed with at least two other subunits. The a6 subunit can form a functional receptor when co-expressed with b4 in vitro, but more efficient expression ensues from incorporation of a third partner, such as b3. The a7, a8, and a9 subunits form functional homo-oligomers, but can also combine with a second a subunit to constitute a hetero-oligomeric assembly (e.g. avian a7a8). For functional expression of the a10 subunit, co-assembly with a9 is necessary. The latter, along with the a10 subunit, appears to be largely confined to cochlear and vestibular hair cells. The nicotinic receptor subcommittee of NC-IUPHAR has recommended a nomenclature and classification scheme for nicotinic acetylcholine (nACh) receptors based on the subunit composition of known, naturally-and/or heterologously-expressed nACh receptor subtypes (Lukas et al., 1999). Headings for this table reflect abbreviations designating nACh receptor subtypes based on the predominant a subunit contained in that receptor subtype. An asterisk following the indicated a subunit denotes that other subunits are known to, or may, assemble with the indicated a subunit to form the designated nACh receptor subtype(s). Where subunit stoichiometries within a specific nACh receptor subtype are known, numbers of a particular subunit larger than 1 are indicated by a subscript following the subunit (enclosed in parentheses).
a(1) 2 bgd: P Ca /P Na B0.3 a(1) 2 bed: P Ca /P Na B0.9
a2b2: P Ca /P Na B1.5 a3b2: P Ca /P Na B1.5; a3b4: P Ca /P Na B1.0, fractional calcium flux=2.7% Nomenclature a4* a6* a7*
Previous names
Neuronal, a-bungarotoxin-insensitive F Neuronal, a-bungarotoxin-sensitive Selective agonists a4b2: TC-2559 (Chen et al., 2003) , RJR-2403 (Papke et al., 2000 , ABT-594 (Donnelly-Roberts et al., 1998) ]-methyllycaconitine, (native ra7*, 1.9 nM) Functional characteristics a4b2: P Ca /P Na B1.5, fractional calcium flux=2.6%
F P Ca /P Na B6 -20, fractional calcium flux=11.4% a4b4: fractional calcium flux=1.5%
A firm consensus has yet to emerge concerning the pharmacological profiles at different nACh receptor subtypes. There are differences in profiles for a given receptor subtype across species. Moreover, measures of agonist potencies and efficacies, or antagonist affinities, are confounded by differences in experimental design across studies (oocyte or mammalian cell heterologous expression systems or natural expression; test agonist concentrations; competitive/noncompetitive modes of antagonism; electrophysiological, ion flux, or calcium ion mobilization measurements, etc.). Therefore, provisional and incomplete information about pharmacological rank order potency profiles (no efficacy data) is provided in the table, based largely on data from studies of heterologously expressed, human nACh receptors. The dagger (w) as superscript designates ligands whose rank order placement differs across species and/or experimental design.
Abbreviations: ABT-594, (R)-5-(2-azetidinylmethoxy)-2-chloropyridine; ACh, acetylcholine; ana-a, anatoxin-a; AR-R17779, (À)-spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one; atr, atropine; Bgt, a-bungarotoxin; bic, bicuculline; car, carbamylcholine; cho, choline; cyt, cytisine; DHbE, dihydro-b-erythroidine; DMAC, 3-(4)-dimethylaminocinnamylidine anabaseine; DMPP, 1,1-dimethyl-4-phenylpiperazinium; epi, epibatidine; GTS-21, 3-(2,4)-dimethoxybenzylidine anabaseine (DMXB); hex, hexamethenium; mec, mecamylamine; MLA, methyllycaconitine; mus, muscarine; nic, nicotine; OH-GTS-21, 3-(4-hydroxy, 2-methoxy)benzylidine anabaseine; pan, pancuronium; PSAB-OFP, LUKAS, R.J., CHANGEUX, J.-P., LE NOVERE, N., ALBUQUERQUE, E.X., BALFOUR, D.J., BERG, D.K., BERTRAND, D., CHIAPPINELLI, V.A., CLARKE, P.B., COLLINS, A.C., DANI, J.A., GRADY, S.R., KELLAR, K.J., LINDSTROM, J.M., MARKS, M.J., QUIK, M., TAYLOR, P.W. & WONNACOTT, S. (1999) . International Union of Pharmacology. XX. Current status of the nomenclature for nicotinic acetylcholine receptors and their subunits. Pharmacol. Rev., 51, 397 -401. MCINTOSH, J.M., SANTOS, A.D. & OLIVERA, B.M. (1999) . Conus peptides targeted to specific nicotinic acetylcholine receptor subtypes. Ann. Rev. Biochem., 68, 59 -88. SCHMITT, J.D. (2000) . Exploring the nature of molecular recognition in nicotinic acetylcholine receptors. Curr. Med. Chem., 7, 749 -800. SKOK, V.I. (2002) . Nicotinic acetylcholine receptors in autonomic ganglia. Auton. Neurosci., 97, 1 -11. TAYLOR, P., MALANZ, S., MOLLES, B.E., OSAKA, H. & TSIGELNY, I. (2000) . Subunit interface selective toxins as probes of nicotinic acetylcholine receptor structure. Pflu¨gers Arch., 440 (Suppl), R115 -R117. (Barnard, 2000; Korpi et al., 2002) . The p subunit is restricted to reproductive tissue. Alternatively spliced versions of a6-(not functional), a5-, b2-, b3-and g2-subunits exist (see Barnard, 2000) . In addition, three r subunits (r1 -3) function as either homo-or hetero-oligomeric assemblies (Bormann & Feigenspan, 2000; Zhang et al., 2001) . Many GABA A receptor subtypes contain a, b and g subunits with the likely stoichiometry 2a.2b.1g (Korpi et al., 2002; Fritschy & Bru¨nig, 2003) . It is thought that the majority of GABA A receptors harbour a single type of a and b subunit variant. The a1b2g2 hetero-oligomer constitutes the largest population of GABA A receptors in the CNS, followed by the a2b3g2 and a3b3g2 isoforms. Receptors that incorporate the a4, a5 or a6 subunit, or the b1, g1, g3, d, e and y subunits, are less numerous, but they may nonetheless serve important functions. The a-and b-subunits contribute to the GABA-binding site and both the a-and g-subunits are required for the benzodiazepine (BDZ) site. The particular a and g subunit isoforms exhibit marked effects on recognition and/or efficacy at the BDZ site. Thus, receptors incorporating either a4 or a6 subunits are not recognized by 'classical' benzodiazepines, such as flunitrazepam. It is beyond the scope of this supplement to discuss the pharmacology of individual receptor isoforms in detail; such information can be gleaned from the reviews by Barnard et al. (1998 ), Frolund et al. (2002 , Korpi et al. (2002) and Krogsgaard-Larsen et al. (2002) . Agents that discriminate between a-subunit isoforms are noted in the table and additional agents that demonstrate selectivity between receptor isoforms are indicated in the text below.
References
The classification of GABA A receptors has been addressed by NC-IUPHAR (Barnard et al., 1998) . The proposed scheme utilizes subunit structure and receptor function as the basis for classification. In view of the fact that a benzodiazepine (BDZ)-binding site is not unique to the GABA A receptor, and that certain receptor isoforms (i.e. those incorporating a4-or a6-subunits) are insensitive to classical benzodiazepines, it is recommended that the term 'GABA A /benzodiazepine receptor complex' should no longer be used and be replaced by 'GABA A receptor'. The term benzodiazepine receptor itself is contentious because receptors should generally be named to reflect their endogenous ligand, and many discriminatory ligands acting at this site are generally not benzodiazepines (e.g. zolpidem, an imidazopyridine). Here, the term 'BDZ site of the GABA A receptor' is adopted as one of the two alternatives proposed by NC-IUPHAR.
The potency and efficacy of many GABA agonists vary between GABA A receptor isoforms (Frolund et al., 2002; Krogsgaard-Larsen et al., 2002) . For example, THIP (gaboxadol) is a partial agonist at receptors with the subunit composition a4b3g2, but elicits currents in excess of those evoked by GABA at the a4b3d receptor, where GABA itself is a low-efficacy agonist (Brown et al., 2002; Bianchi & MacDonald, 2003) . The GABA A receptor contains distinct allosteric sites that bind barbiturates and endogenous (e.g. 5a-pregnan-3a-ol-20-one) and synthetic (e.g. alphaxalone) neuroactive steroids in a diastereo-or enantio-selective manner (see Lambert et al., 2003) . Picrotoxinin and TBPS act at an allosteric site within the chloride channel pore to negatively regulate channel activity; negative allosteric regulation by g-butyrolactone derivatives also involves the pictrotoxinin site, whereas positive allosteric regulation by such compounds is proposed to occur at a distinct locus. Many intravenous (e.g. etomidate, propofol) and volatile (e.g. halothane, isoflurane) anaesthetics and alcohols also exert a regulatory influence upon GABA A receptor activity. Specific amino-acid residues within GABA A receptor a-and b-subunits that influence allosteric regulation by anaesthetic and nonanaesthetic compounds have been identified (see Belelli et al., 1999; Krazowski et al., 2000; Thompson & Wafford, 2001 ).
In addition to the agents listed in the table, modulators of GABA A receptor activity that exhibit subunit-dependent activity include: loreclezole, etomidate, tracazolate and mefenamic acid (positive allosteric modulators with selectivity for b2/b3 over b1 subunit-containing receptors, see Korpi et al. (2002) ; tracazolate (intrinsic efficacy, that is, potentiation, or inhibition, is dependent upon the identity of the g1 -3, delta, or epsilon subunit co-assembled with a1 and b1 subunits (Thompson et al., 2002) ); amiloride (selective blockade of receptors containing an a6 subunit (Fisher, 2002)); frusemide (selective blockade of receptors containing an a6 subunit coassembled with b2/b3, but not b1, subunit (see Korpi et al. (2002) ); La 3 þ (potentiates responses mediated by a1b3g2L receptors, weakly inhibits a6b3g2L receptors, and strongly blocks a6b3d receptors (Saxena et al., 1997)). It should be noted that the apparent selectivity of some positive allosteric modulators (e.g. neurosteroids such as 5a-pregnan-3a-ol-20-one for d-subunit-containing receptors (e.g. a4b3d) may be a consequence of the unusually low efficacy of GABA at this receptor isoform (Bianchi et al., 2003) .
A bicuculline-and baclofen-insensitive site has been located in cerebellum using cis-4-aminocrotonic acid. A subpopulation of retinal GABA receptors (activated by trans-4-aminocrotonic acid) assembled from r subunits is similarly bicuculline-insensitive and gates Cl À channels that are insensitive to barbiturates and benzodiazepines and selectively blocked by TPMPA. Isoguvacine, THIP and piperidine-4-sulphonic acid do not activate GABA A receptors assembled from r subunits. Receptors formed from r subunits have often been found to be insensitive to neuroactive steroids (see Bormann, 2000) , but relatively high concentrations of such compounds can modulate the activity of the r1 subunit in a stereoselective manner, 5a-pregnanes potentiating, and 5b-pregnanes inhibiting, responses elicited by low concentrations of GABA. Although these receptors have sometimes been termed GABA C receptors (see Bormann, 2000; Zhang, 2001) , they may represent a subpopulation of GABA A receptors, classed as the GABA A0r subtype, under NC-IUPHAR proposals (Barnard et al., 1998) . This suggestion is strengthened by the observation that single amino-acid mutations can impart some features of GABA A receptor pharmacology upon the GABA A0r subtype (Belelli et al., 1999; Walters et al., 2000) .
Ensembl family ID ENSF00000000053 Selective agonists (GABA site)
Muscimol, isoguvacine, THIP (gaboxadol), piperidine-4-sulphonic acid (low efficacy at a4 and a6 subunits), isonipecotic acid (a4 and a6 subunit selective via relatively high efficacy) Selective antagonists (GABA site) Bicuculline, gabazine (SR95531) Selective agonists (BDZ site) Diazepam (not a4-or a6-subunits), flunitrazepam (not a4-or a6-subunits), zolpidem and zaleplon (a1 subunit selective via high affinity), L838417 (a2, a3 and a5 subunit selective via partial agonist activity), Selective antagonists (BDZ site) Flumazenil (low affinity for a4-or a6-subunits), L838417 (a1 subunit selective via antagonist activity) ZK93426 Inverse agonists (BDZ site) DMCM, Ro194603, L655708 (a5 selective via high affinity), RY024 (a5 selective via high affinity) Endogenous allosteric modulators 5a-pregnan-3a-ol-20-one (potentiation), Zn 2+ (potent inhibition of receptors formed from binary combinations of a and b subunit, incorporation of a g subunit reduces inhibitory potency, Krishek et al., 1998) Overview: The ionotropic glutamate receptors comprise members of the NMDA (N-methyl-D-aspartate), AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) and kainate receptor classes, named originally according to their preferred, synthetic, agonist (see Dingledine et al. (1999) for a comprehensive review). Receptor heterogeneity within each class arises from the homo-oligomeric, or hetero-oligomeric, assembly of distinct subunits into cation-selective tetramers. All glutamate receptor subunits have the membrane topology of an extracellular N-terminus, three transmembrane domains (TM1, TM3 and TM4), a channel lining re-entrant 'p-loop' (MD2) located between TM1 and TM3 that enters and exits the membrane at its cytoplasmic surface, and an intracellular C-terminus (see Madden, 2002) . It is beyond the scope of this supplement to discuss the pharmacology of individual ionotropic glutamate receptor isoforms in detail; such information can be gleaned in the reviews by Dingledine et al. (1999) , Yamakura & Shimoji (1999) , Jane et al. (2000) , Cull-Candy et al. (2001) and Huettner (2003) . Agents that discriminate between subunit isoforms are, where appropriate, noted in the tables and additional compounds that distinguish between receptor isoforms are indicated in the text below.
The classification of glutamate receptors has been addressed by NC-IUPHAR (Lodge & Dingledine, 2000) . The proposed scheme, which recommends a revised nomenclature for ionotropic glutamate receptor subunits, is adopted here. Commonly used alternative appellations are indicated in parenthesis.
NMDA receptors: NMDA receptors assemble as heteromers that may be drawn from GLU N1 (NMDA-R1, NR1, GluRx1), GLU N2A (NMDA-R2A, NR2A, GluRe1), GLU N2B (NMDA-R2B, NR2B, GluRe2), GLU N2C (NMDA-R2C, NR2C, GluRe3), GLU N2D (NMDA-R2D, NR2D, GluRe4), GLU N3A (NMDA-R3A) and GLU N3B (NMDA-R3B) subunits. Alternative splicing can generate eight isoforms (one nonfunctional) of GLU N1 with differing pharmacological properties. Various splice variants of GLU N2B,2C,2D and GLU N3A have also been reported (see Cull-Candy et al., 2001) . Activation of NMDA receptors requires the binding of two agonists, glutamate to the GLU N2 subunit and glycine to the GLU N1 subunit. The minimal requirement for efficient functional expressional of NMDA receptors in vitro is a diheteromeric assembly of GLU N1 and at least one GLU N2 subunit variant, most likely in a dimer of dimers arrangement (Madden, 2002) . However, more complex triheteromeric assemblies, incorporating multiple subtypes of GLU N2 subunit, or GLU N3 subunits, can be generated in vitro and occur in vivo. The NMDA receptor channel commonly has a high relative permeability to Ca 2 þ and is blocked, in a voltage-dependent manner, by Mg 2 þ at resting potential.
In addition to the glutamate and glycine binding sites documented in the table, physiologically important inhibitory modulatory sites exist for Mg 2 þ , Zn 2 þ and protons (see Dingledine et al., 1999; Yamakura & Shimoji, 1999; Cull-Candy et al., 2001 ). The receptor is also allosterically modulated, in both positive and negative directions, by endogenous neuroactive steroids in a subunit-dependent manner. For example, pregnenolone sulphate potentiates diheteromeric assemblies of GLU N1 /GLU N2A and GLU N1 /GLU N2B subunits, but inhibits receptors assembled as GLU N1 /GLU N2C , or GLU N1 /GLU N2D , heteromers (Malayev et al., 2002) . Tonic proton blockade of NMDA receptor function is alleviated by polyamines and the inclusion of exon 5 within GLU N1 subunit splice variants, whereas the noncompetitive antagonist ifenprodil increases the fraction of receptors blocked by protons at ambient concentration. Receptors assembled from GLU N1 and GLU N2C subunits are unusually insensitive to proton blockade. Ifenprodil, its analogue CP101606, haloperidol, felbamate and Ro84304 discriminate between recombinant NMDA receptors assembled from GLU N1 and either GLU N2A , or GLU N2B , subunits by acting as selective, noncompetitive, antagonists of heterooligomers incorporating GLU N2B . LY233536 is a competitive antagonist that also displays selectivity for GLU N2B over GLU N2A subunit-containing receptors. Similarly, CGP61594 is a photoaffinity label that interacts selectively with receptors incorporating GLU N2B versus GLU N2A , GLU N2D and, to a lesser extent, GLU N2C subunits. Conversely, the voltage-independent component of NMDA receptor inhibition by Zn 2 þ is most pronounced for receptors that contain the GLU N2A versus GLU N2B subunit. In addition to influencing the pharmacological profile of the NMDA receptor, the identity of the GLU N2 subunit co-assembled with GLU N1 is an important determinant of biophysical properties that include sensitivity to block by Mg 2 þ , single-channel conductance and channel deactivation time (Cull-Candy et al., 2001) . Incorporation of the GLU N3A subunit into triheteromers containing GLU N1 and GLU N2 subunits is associated with decreased single-channel conductance, reduced permeability to Ca 2 þ and decreased susceptibility to block by Mg 2 þ . Reduced permeability to Ca 2 þ has also been observed following the inclusion of GLU N3B in triheteromers.
AMPA and kainate receptors: AMPA receptors assemble as homomers, or heteromers, that may be drawn from GLU A1 (GluR1, GluRA, GluR-A, GluR-K1), GLU A2 (GluR2, GluRB, GluR-B, GluR-K2), GLU A3 (GluR3, GluRC, GluR-C, GluR-K3), or GLU A4 (GluR4, GluRD, GluR-D) subunits. Homotetramers formed from GLU A2 subunits express relatively poorly due to their retention within the endoplasmic reticulum (see Bredt & Nicoll, 2003) . Functional kainate receptors can be expressed as homomers of GLU K5 (GluR5, GluR-5, EAA3), GLU K6 (GluR6, GluR-6, EAA4), or GLU K7 (GluR7, GluR-7, EAA5) subunits. GLU K5 -7 subunits are also capable of assembling into heterotetramers (see Lerma, 2003) . Two additional kainate receptor subunits, GLU K1 (KA1, KA-1, EAA1) and GLU K2 (KA2, KA-2, EAA2), when expressed individually, form high-affinity binding sites for kainate, but lack function (see Heuttner, 2003) . GLU K1 and GLU K2 can form heteromers when co-expressed with GLU K5 -7 subunits (Lerma, 2003) . RNA encoding the GLU A2 subunit undergoes extensive RNA editing in which the codon encoding a p-loop glutamine residue (Q) is converted to one encoding arginine (R). This Q/R site strongly influences the biophysical properties of the receptor. Recombinant AMPA receptors lacking RNA-edited GLU A2 subunits are:
(1) permeable to Ca 2 þ ; (2) blocked by intracellular polyamines at depolarized potentials causing inward rectification; (3) blocked by extracellular argiotoxin and Joro spider toxins and (4) demonstrate higher channel conductances than receptors containing the edited form of GLU A2 (Seeburg & Hartner, 2003) . GLU K5 and GLU K6 , but not other kainate receptor subunits, are similarly edited and broadly similar functional characteristics apply to kainate receptors lacking either an RNA-edited GLU K5 , or GLU K6 , subunit (Lerma, 2003) . Native AMPA and kainate receptors displaying differential channel conductances, Ca 2 þ permeabilites and sensitivity to block by intracellular polyamines have been identified. GLU A1 -4 can exist as two variants generated by alternative splicing (termed 'flip' and 'flop') that differ in their desensitization kinetics and their desensitization in the presence of cyclothiazide. Splice variants of GLU K5 -7 also exist, but their functional significance is unknown (Lerma, 2003) . 
S66 Glutamate (ionotropic)
Alexander et al Glutamate (ionotropic)
Overview:
The inhibitory glycine receptor is a member of the cys-loop superfamily of transmitter-gated ion channels that includes the GABA A , nicotinic acetylcholine and 5-HT 3 receptors. Structurally and functionally, the glycine receptor is most closely related to the GABA A receptor. The receptor is expressed either as a homo-(a subunit) or hetero-(3a:2b subunits) pentameric assembly containing an intrinsic Cl À channel. Four differentially expressed isoforms of the a-subunit (a1 -a4) and one variant of the b-subunit (b1) have been identified by genomic and cDNA cloning. Further diversity originates from alternative splicing of the a1, a2 and a3 subunits. In addition, a rat specific a2 subunit variant (termed a2*) demonstrates greatly reduced affinity towards glycine and strychnine. Predominantly, the mature form of the receptor contains a1 (or a3) and b subunits, while the immature form is mostly composed of only a2 subunits. RNA transcripts encoding the a4 subunit have not been detected in adult humans. The a4 subunit may be a pseudogene in man and is not tabulated here. The N-terminal domain of the a-subunit contains both the agonist-and strychnine-binding sites that consist of several discontinuous regions of amino acids. Inclusion of the b-subunit in the pentameric glycine receptor reduces single channel conductance and alters pharmacology. It also anchors the receptor, via an amphipathic sequence within the intracellular loop region, to gephyrin, a cytoskeletal attachment protein, that binds to tubulin and thus clusters and anchors hetero-oligomeric receptors to the synapse (see Kneussel & Betz, 2000; Moss & Smart, 2001) . There is no NC-IUPHAR recommendation for the classification of glycine receptors. The provisional nomenclature adopted here classifies glycine receptor isoforms according to their a-subunit.
Data in the table refer to homo-oligomeric assemblies of the a-subunit; significant changes introduced by co-expression of the b1 subunit (ENSG00000109738) are indicated in parenthesis. Not all glycine receptor ligands are listed within the table, but those that may be useful in distinguishing between glycine receptor isoforms are indicated. Pregnenolone sulphate, tropisetron and colchicine, for example, although not selective antagonists of glycine receptors, are included for this purpose. Strychnine is the most potent and selective competitive glycine receptor antagonist with affinities in the range 5 -15 nM. Several analogues of muscimol and piperidine act as agonists and antagonists of both glycine and GABA A receptors. Picrotoxin has been reported to block the chloride channel of glycine receptors (Pribilla et al., 1992) or, by contrast, to act as a competitive antagonist (Lynch et al., 1995) . Picrotoxin shows strong selectivity towards homomeric receptors composed of a subunits (Pribilla et al., 1992; Lynch et al., 1995) , and its components, picrotoxinin and picrotin, have similar inhibitory potencies. In addition to the compounds listed in the table, numerous agents act as allosteric regulators of glycine receptors (reviewed by Rajendra et al., 1997; Laube et al., 2002) . Zn 2 þ acts through distinct binding sites of high and low affinity to allosterically enhance channel function at low (o10 mM) concentrations and inhibit responses at higher (>50 -100 mM) concentrations. The effect of Zn 2 þ is mimicked by Ni 2 þ . Elevation of intracellular Ca 2 þ produces fast potentiation of glycine receptor-mediated responses. Dideoxyforskolin (4 mM) and tamoxifen (0.2 -5 mM) both potentiate responses to low glycine concentrations (15 mM), but act as inhibitors at higher glycine concentrations (100 mM). Additional modulatory agents that enhance glycine receptor function include inhalational, and several intravenous general anaesthetics (e.g. minaxolone, propofol and pentobarbitone) and certain neurosteroids. Ethanol and higher order n-alcohols also act allosterically to enhance glycine receptor function. Solvents inhaled as drugs of abuse (e.g. toluene, 1-1-1-trichloroethane) may act at sites that overlap with those recognising alcohols and volatile anaesthetics to produce potentiation of glycine receptor function. The function of glycine receptors formed as homomeric complexes of a1 or a2 subunits, or hetero-oligomers of a1/b or a2/b subunits, is differentially affected by the 5-HT 3 receptor antagonist tropisetron , which may evoke potentiation or inhibition depending upon the subunit composition of the receptor and the concentrations of the modulator and glycine employed (Maksay et al., 1999; Supplisson & Chesnoy-Marchais, 2000) . Additional tropienes, including atropine, modulate glycine receptor activity.
Abbreviations:
aEMBTL, a-ethyl,a-methyl-g-thiobutyrolactone; BN52021, (7)-trans-2,5-bis (3,4,5-trimethoxyphenyl 
S68 Glycine
Alexander et al (Surprenant et al., 1996) .
Agonists listed show selectivity within recombinant P2X receptors of ca. one order of magnitude. Several P2X receptors (particularly P2X 1 and P2X 3 ) may be inhibited by desensitisation using stable agonists (e.g. ab-meATP); suramin and PPADS are nonselective antagonists at rP2X 1 -3,5 and hP2X 4 , but not rP2X 4,6,7 (Buell et al., 1996) , and can also inhibit ATPase activity (Crack et al., 1994) . Ip 5 I is inactive at rP2X 2 , an antagonist at rP2X 3 (pIC 50 5.6) , and enhances agonist responses at rP2X 4 (King et al., 1999) . Antagonist potency of NF023 at recombinant P2X 2 , P2X 3 and P2X 5 is two orders of magnitude lower than that at P2X 1 receptors (Soto et al., 1999) . Some recombinant P2X receptors expressed to high density bind [ D. et al. (1995) . Br. J. Pharmacol., 115, 767 -774. SOTO, F. et al. (1999) . Neuropharmacology, 38, 141 -149. SURPRENANT, A. et al. (1996) . Science, 272, 735 -738. VIRGINIO, C. et al. (1998 
